John T Lucas1, David A Cooper2, Scott Hwang3, Christopher Tinkle4, Xingyu Li5, Yimei Li5, Brent Orr6, Thomas E Merchant4, Alberto Broniscer7. 1. Department of Radiation Oncology, St Jude Children's Research Hospital, Memphis, Tennessee. Electronic address: john.lucas@stjude.org. 2. College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. 3. Department of Diagnostic Imaging, St Jude Children's Research Hospital, Memphis, Tennessee. 4. Department of Radiation Oncology, St Jude Children's Research Hospital, Memphis, Tennessee. 5. Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee. 6. Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee. 7. Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee; Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee.
Abstract
PURPOSE: We sought to investigate the pattern of treatment failure with respect to anatomic extent, radiation dose, and criteria for failure according to the Response Assessment in Neuro-Oncology (RANO). We evaluated the corresponding prognostic significance of these factors in patients with pediatric high-grade glioma (pHGG). METHODS AND MATERIALS: Fifty-six patients with pHGG were enrolled in an institutional phase 1 to 2 prospective trial that included maximal safe resection and radiation therapy with concurrent and adjuvant erlotinib. The radiation therapy dose administered was 54 to 59.4 Gy at 1.8 Gy/d. Tumor progression was defined according to clinical symptoms and imaging features and was classified in relation to the original extent of the tumor, radiation prescription target volume coverage, and RANO criteria (RANOc). RESULTS: With a median follow-up period of 90 months (range, 70-124 months), progression occurred in 48 patients (85.7%) while 8 (14.3%) were without progression. Central failure represented 42.6% of the total cohort, while in-field, marginal, and distant failures occurred in 7.4%, 9.3%, and 22.2%, respectively. Patients with biopsy or subtotal resection had increased rates of central failure and represented 14.81% and 16.67% of the total cohort, respectively. Tumor progression was classified as local, local plus distant, or distant. Among patients with local failure as a component of failure, 5 were considered to have marginal failure. Patients with frontal, temporal, and parietal disease had the highest rates of multifocal failure. A comparison between responses defined by RANOc demonstrated varied time to death (TTD) from progression. CONCLUSIONS: Pediatric high-grade glioma was shown to have high rates of central failure, particularly in cases with limited resection. Patients with central failure had a trend toward more prolonged TTD from failure relative to other failure patterns. The low marginal failure rates seen in this group suggest that less conservative radiation target margins may be possible. TTD from failure varied according to RANO type, suggesting that adult RANOc require modification before being applied to pHGG.
PURPOSE: We sought to investigate the pattern of treatment failure with respect to anatomic extent, radiation dose, and criteria for failure according to the Response Assessment in Neuro-Oncology (RANO). We evaluated the corresponding prognostic significance of these factors in patients with pediatric high-grade glioma (pHGG). METHODS AND MATERIALS: Fifty-six patients with pHGG were enrolled in an institutional phase 1 to 2 prospective trial that included maximal safe resection and radiation therapy with concurrent and adjuvant erlotinib. The radiation therapy dose administered was 54 to 59.4 Gy at 1.8 Gy/d. Tumor progression was defined according to clinical symptoms and imaging features and was classified in relation to the original extent of the tumor, radiation prescription target volume coverage, and RANO criteria (RANOc). RESULTS: With a median follow-up period of 90 months (range, 70-124 months), progression occurred in 48 patients (85.7%) while 8 (14.3%) were without progression. Central failure represented 42.6% of the total cohort, while in-field, marginal, and distant failures occurred in 7.4%, 9.3%, and 22.2%, respectively. Patients with biopsy or subtotal resection had increased rates of central failure and represented 14.81% and 16.67% of the total cohort, respectively. Tumor progression was classified as local, local plus distant, or distant. Among patients with local failure as a component of failure, 5 were considered to have marginal failure. Patients with frontal, temporal, and parietal disease had the highest rates of multifocal failure. A comparison between responses defined by RANOc demonstrated varied time to death (TTD) from progression. CONCLUSIONS: Pediatric high-grade glioma was shown to have high rates of central failure, particularly in cases with limited resection. Patients with central failure had a trend toward more prolonged TTD from failure relative to other failure patterns. The low marginal failure rates seen in this group suggest that less conservative radiation target margins may be possible. TTD from failure varied according to RANO type, suggesting that adult RANOc require modification before being applied to pHGG.
Authors: Barbara S Paugh; Chunxu Qu; Chris Jones; Zhaoli Liu; Martyna Adamowicz-Brice; Junyuan Zhang; Dorine A Bax; Beth Coyle; Jennifer Barrow; Darren Hargrave; James Lowe; Amar Gajjar; Wei Zhao; Alberto Broniscer; David W Ellison; Richard G Grundy; Suzanne J Baker Journal: J Clin Oncol Date: 2010-05-17 Impact factor: 44.544
Authors: Heather J McCrea; Evan D Bander; Rachael A Venn; Anne S Reiner; J Bryan Iorgulescu; Luis A Puchi; Peter M Schaefer; Gustav Cederquist; Jeffrey P Greenfield Journal: Neurosurgery Date: 2015-09 Impact factor: 4.654
Authors: R Sposto; I J Ertel; R D Jenkin; C P Boesel; J L Venes; J A Ortega; A E Evans; W Wara; D Hammond Journal: J Neurooncol Date: 1989-07 Impact factor: 4.130
Authors: Martin J van den Bent; Michael A Vogelbaum; Patrick Y Wen; David R Macdonald; Susan M Chang Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Andrew E Sloan; Manmeet S Ahluwalia; Jose Valerio-Pascua; Sunil Manjila; Mark G Torchia; Stephen E Jones; Jeffrey L Sunshine; Michael Phillips; Mark A Griswold; Mark Clampitt; Cathy Brewer; Jennifer Jochum; Mary V McGraw; Dawn Diorio; Gail Ditz; Gene H Barnett Journal: J Neurosurg Date: 2013-04-05 Impact factor: 5.115
Authors: Hadie Adams; Hieab H H Adams; Christina Jackson; Jordina Rincon-Torroella; George I Jallo; Alfredo Quiñones-Hinojosa Journal: Childs Nerv Syst Date: 2016-01-15 Impact factor: 1.475
Authors: Ibrahim Qaddoumi; Mehmet Kocak; Atmaram S Pai Panandiker; Gregory T Armstrong; Cynthia Wetmore; John R Crawford; Tong Lin; James M Boyett; Larry E Kun; Fredrick A Boop; Thomas E Merchant; David W Ellison; Amar Gajjar; Alberto Broniscer Journal: Front Oncol Date: 2014-04-01 Impact factor: 6.244
Authors: John T Lucas; Christopher L Tinkle; Jie Huang; Arzu Onar-Thomas; Sudharsan Srinivasan; Parker Tumlin; Jared B Becksfort; Paul Klimo; Frederick A Boop; Giles W Robinson; Brent A Orr; Julie H Harreld; Matthew J Krasin; Paul A Northcott; David W Ellison; Amar Gajjar; Thomas E Merchant Journal: Neuro Oncol Date: 2022-07-01 Impact factor: 13.029
Authors: Aleksandra Napieralska; Aleksandra Krzywon; Agnieszka Mizia-Malarz; Joanna Sosna-Zielińska; Ewa Pawłowska; Małgorzata A Krawczyk; Katarzyna Konat-Bąska; Aneta Kaczorowska; Anna Dąbrowska; Maciej Harat Journal: Cancers (Basel) Date: 2021-04-24 Impact factor: 6.639